A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma
Introduction
Patients with a ‘high-risk’ soft-tissue sarcoma [1] have a 50% risk of developing distant metastases with subsequent poor survival.
Several prospective randomised trials, comparing adjuvant chemotherapy after surgery to surgery alone, have produced controversial results [2]. Zalupski and colleagues [3] concluded from a meta-analysis that was performed on data from publications, that there was a statistically significant improvement in disease-free and overall survival in favour of chemotherapy. An international collaborative group [4] concluded from their meta-analysis performed on the actual study data (a more valid way of performing meta-analysis) comprising 1568 patients from 14 trials that adjuvant doxorubicin-based chemotherapy significantly increased the time to local and distant recurrence and recurrence-free survival. However, there was only a trend towards improved overall survival with the result that adjuvant chemotherapy is still not regarded by many as standard treatment.
The timing of chemotherapy as an adjuvant to surgery is a topic for ongoing debate. In several other malignancies, e.g. head and neck cancers, bladder cancer, osteosarcomas and inflammatory breast cancer, neo-adjuvant-chemotherapy preceding surgery is now preferred. Such chemotherapy is associated with better patient compliance and has no negative impact on the potential of local treatment.
In view of this the European Organization for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) designed a study to investigate the feasibility and outcome of neo-adjuvant-chemotherapy in adult soft-tissue sarcomas.
As the possibility that disease progression during chemotherapy might render patients inoperable was a major concern, the study was designed as a phase II/III trial. Only if progression during chemotherapy was infrequent and accrual appeared to be appropriate would the study proceed to phase III. Due to limited accrual, however, the study was terminated at the end of phase II. Preliminary results have been presented in abstract previously [5]. This is presently still the only randomised trial of neo-adjuvant-chemotherapy in soft-tissue sarcoma and here we report the results after a median follow-up of 7.3 years.
Section snippets
Patients and methods
The design of the trial is shown in Fig. 1.
Patient characteristics
150 patients were entered into this study by 23 centres. Seventy percent of all patients were entered by five centres. The accrual rate was initially extremely low. It thereafter varied considerably over time, in some periods tending to increase to such an extent that with a further increase extension into the phase III study would have become possible. However, despite various efforts to further increase accrual, it finally dropped again to such unacceptably low rates that continuation could
Discussion
The concept of neo-adjuvant chemotherapy is a topic for ongoing debate. The outcome of non-randomised phase II studies of neo-adjuvant chemotherapy suggest that chemotherapy given at this stage of the disease gives a higher response rate than chemotherapy given for distant metastases 7, 8, 9. This suggestion would be consistent with similar data available from treatment in tumours such as osteosarcoma, head and neck cancer, breast cancer 9, 10, bladder cancer and various other types of
References (16)
- et al.
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
Eur. J. Cancer
(2000) - et al.
Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma — reduced local recurrence but no improvement in survivala study of the European Organization for Research and Treatment of Cancer. Soft tissue sarcoma group
J. Clin. Oncol.
(1994) - et al.
Soft tissue sarcomamessages of completed randomized trials
Eur. J. Surg. Onc.
(1995) - Zalupski MM, Ryan JR, Hussein ME, et al. Defining the role of adjuvant chemotherapy for patients with soft tissue...
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adultmeta-analysis of individual data
Lancet
(1997)- et al.
Randomised phase II study of neoadjuvant chemotherapy in soft tissue sarcomas in adults. Protocol 62874
Eur. J. Cancer
(1993) - WHO Handbook for Reporting Results of Cancer Treatment. Geneva, WHO, 1979,...
- et al.
Pre-operative neo-adjuvant chemotherapy in the treatment of locally advanced soft tissue sarcomas
Cancer
(1987)
Cited by (311)
Evidence for the Current Management of Soft-tissue Sarcoma and Gastrointestinal Stromal Tumors and Emerging Directions
2023, Surgical Oncology Clinics of North AmericaWide Resection of Extremity/Truncal Soft Tissue Sarcomas
2022, Surgical Clinics of North AmericaSoft Tissue Sarcomas: The Role of Quantitative MRI in Treatment Response Evaluation
2022, Academic RadiologyTeam Approach: Extremity Soft Tissue Sarcoma
2023, JBJS Reviews
- 1
Present address: Istituto Clinico Humanitas, Rozzano, Milano, Italy.